Brimonidine (Alphagan) is contraindicated in patients taking which class of medication?

Brimonidine is an alpha-2 adrenergic agonist primarily used to treat glaucoma by reducing intraocular pressure. It acts through its agonistic properties on adrenergic receptors, which can influence neurotransmitter release.

The contraindication with monoamine oxidase inhibitors (MAOIs) arises because brimonidine's action can be potentiated by the inhibition of monoamine oxidase. MAOIs prevent the breakdown of catecholamines, leading to increased levels of norepinephrine and dopamine in the body. When brimonidine is used simultaneously with MAOIs, it can result in excessive adrenergic stimulation, which may lead to elevated blood pressure or other adverse cardiovascular effects.

Understanding the interaction between brimonidine and MAOIs is crucial, as the combination has the potential to cause significant clinical issues that can compromise patient safety. This highlights the importance of careful medication management in patients with different conditions and those on various therapies.